Supporting Information

Functional Modification of Electrospun PCL Vascular Grafts with the Fusion Protein VEGF-HGFI Enhanced Vascular Regeneration

Kai Wang,1# Qiuying Zhang,1# Liqiang Zhao,2 Yiwa Pan,1 Ting Wang,3 Dengke Zhi,1 Shaoyang Ma,1 Peixin Zhang,1 Tiechan Zhao,4 Siming Zhang,4 Wen Li,1 Meifeng Zhu,1 Yan Zhu,4 Jun Zhang,1,* Mingqiang Qiao,2,* Deling Kong1,*

1 Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin 300071, China

2 Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, College of Life Sciences, Nankai University, Tianjin 300071, China

3 Urban Transport Emission Control Research Centre, College of Environmental Science and Engineering, Nankai University, Tianjin 300071, China

4 Center for Research and Development of Chinese Medicine, Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

# Authors contributed equally to this work

Corresponding authors:

Dr. Deling Kong: kongdeling@nankai.edu.cn
Dr. Mingqiang Qiao: qiaomq@nankai.edu.cn
Dr. Jun Zhang: nankaizhangjun@nankai.edu.cn
Figure S1. The stress–strain curves of the three types of grafts. There was no significant difference among the three groups.
Figure S2. The endothelium coverage of the explanted grafts was observed by SEM after 1 month implantation.
Figure S3. Smooth muscle regeneration in the modified or unmodified PCL grafts at 1 month after implantation. A: Longitudinal section was immunostained by mouse anti-alpha smooth muscle actin (a-SMA) antibody (Green). B: Quantitative analysis of the a-SMA^+ SMCs coverage rate on vascular grafts. (C) Quantitative analysis of the a-SMA^+ SMCs area in vascular grafts, * p< 0.05. Red arrows: suturing site.
Table S1. Blood coagulation test of modified or unmodified PCL grafts.

<table>
<thead>
<tr>
<th></th>
<th>PCL</th>
<th>HGFI-PCL</th>
<th>(VEGF-HGFI) -PCL</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>TT (s)</td>
<td>17.40±0.12</td>
<td>17.13±0.07</td>
<td>17.40±0.00</td>
<td>17.23±0.07</td>
</tr>
<tr>
<td>APTT (s)</td>
<td>30.30±0.10</td>
<td>30.10±0.21</td>
<td>29.60±0.15</td>
<td>29.23±0.03</td>
</tr>
<tr>
<td>PT (s)</td>
<td>11.33±0.03</td>
<td>11.20±0.06</td>
<td>11.23±0.03</td>
<td>11.07±0.03</td>
</tr>
</tbody>
</table>

The Clotting time of human plasma without any interference was also tested as control group. PT: Prothrombin time; APTT: Activated partial thromboplastin time; TT: Thrombin time.